Literature DB >> 7762268

A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections.

M A de la Maza1, L M de la Maza.   

Abstract

We describe a new computer model for studying the impact of vaccination protocols on the prevalence of disease. This state transition model uses two parameters, the forward rate and the cure rate, that are derived from epidemiological data to compute the percentage of individuals infected in the population. The cure rate is the percentage of individuals that are cured within one time step (which in this study is one year) and the forward rate is used to calculate the number of new infections due to transmission. The forward rate and the cure rate are incorporated into an update function that has the property that if the vaccination efficacy is 0%, or no vaccination is applied, then the percentage of individuals infected stays constant. We present computer simulations of this model designed to assess the influence of two variables on the prevalence of Chlamydia trachomatis infection in a study population. More specifically, we determined the effect of vaccines with efficacies ranging from 50% to 100% and we analysed the impact on the population for vaccines efficacious for periods of 10, 20 and 40 years. The results of the computer simulation show that even the least efficacious vaccination programme rapidly decreases the prevalence of C. trachomatis infection in the population. On the other hand, a vaccine that is efficacious for a period of only 1 year had minimal impact on the prevalence of the disease in the total population.

Entities:  

Mesh:

Year:  1995        PMID: 7762268     DOI: 10.1016/0264-410x(95)80022-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

3.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

4.  Evolutionary dynamics of ompA, the gene encoding the Chlamydia trachomatis key antigen.

Authors:  Alexandra Nunes; Maria J Borrego; Baltazar Nunes; Carlos Florindo; João P Gomes
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

5.  A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection.

Authors:  Sandra G Morrison; Richard P Morrison
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

6.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

8.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

9.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.